Loading...
Epidermal growth factor receptor (EGFR)–targeted agents with chemotherapy improve response, progression-free survival (PFS), and overall survival (OS) in patients with left-sided, RAS wild-type metastatic colorectal cancer (MCC). Recent trials have attempted to deescalate therapy using maintenance treatment with targeted agents alone or combined with chemotherapy.
Investigators now report results of the industry-supported, open-label, randomized, noninferiority, phase II VALENTINO trial, in which 229 patients with RAS wild-type MCC received eight cycles of first-line chemotherapy with FOLFOX plus panitumumab and were then randomized to maintenance therapy with panitumumab alone or panitumumab with chemotherapy (infusional 5-FU and leucovorin…